open access
메뉴
open access
메뉴
ISSN : 0376-4672
The vitamin K antagonist (VKA), cumadin, or warfarin, is the only antithrombotic drug that can be orally administered and has excellent effective for decades. However, it is cumbersome to periodically inspect the prothrombin time (PT) order to maintain adequate concentrations that do not cause bleeding, takes a few days to indicate therapeutic effects, gets affected by several factors such as food and drugs etc, and narrow in the therapeutic range. Although recently in development, the non-vitamin K antagonist anticoagulants(NOACs) exhibit a rapid onset of action and have relatively short half- lives compared to Coumadin. Because of these pharmacokinetic properties, it is possible to modify an individual's anticoagulation status quite rapidly, minimizing the period where the anticoagulation activity is therapeutically sub-optimal. And the short half -lives of these drug allow for the relatively rapid reduction of their anticoagulation effects. There are currently no published clinical trials specifically assessing the bleeding risks associated with dental procedures for patients taking the NOACs. It is not necessary to interrupt NOAC medication for dental procedures that are likely to cause bleeding, but which have a low risk of bleeding complications. Because the bleeding risk for these procedures is considered to be low, the balance of effects is in favour of continuing the NOAC treatment without modification, to avoid increasing the risk of a thromboembolic event. The patients should be advised to miss(apixaban or dabigatran) or delay(rivaroxaban) a dose of their NOAC prior to dental procedures that are likely to cause bleeding and which have a higher risk of bleeding complications. Because the risk of bleeding complications for these procedures is considered to be higher, the balance effects is in favour of missing or delaying the pre-treatment NOAC dose. The interruption is only for a short time to minimize the effect on thromboembolic risk,
1) Shapiro SS. Treating thrombosis in the 21st century. N Engl J Med 2003; 349:1762-1764.
2) Sinauridze E.I., Panteleev M.A., Ataulla khanov F.I.Anticoagulant therapy: basic principles, classic approaches and recent developments. Blood Coagul Fibrinolysis 2012; 23:482-493.
3) righton T.: New oral anticoagulant drugs- mechanisms of action, Aust Prescr 2010; 33:38-41.
4) Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361:1139-1151.
5) Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365:883-891 .
6) Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365:981-992.
7) Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013; 369:2093-2104.
8) Lip GY, Camm AJ, Hylek EM, et al. Non-vitaminK antagonist oral anticoagulants: an appeal for consensus on terminology. Chest 2014; 145:1177-1178.
9) Mani H, Lindhoff-Last E. New oral anticoagulants in patients with nonvalvular atrial fibrillation: a review of pharmacokinetics, safety, efficacy, quality of life, and cost effectiveness. Drug Des Devel Ther 2014; 8:789-798.
10) Mueck W, Kubitza D, Becka M. Co-administration of rivaroxaban with drugs that share its elimination pathways: pharma cokinetic effects in healthy subjects. Br J Clin Pharmaocl 2013; 76:455-466.
11) Wang L, Zhang D, Raghavan N, et al. In vitro assessment of metabolic drug-drug interaction potential of apixaban through cytochrome P450 phenotyping, inhibition, and induction studies. Drug Metab Dispos 2010; 38:448-458.
12) F. Schiele, J. van Ryn, K. Canada, et al., A specific antidote for dabigatran: functional and structural characterization, Blood 2013; 121: 3554-3562.
13) DeWald TA, Becker RC: The pharmacology of novel oral anticoagulants. J Thromb Thrombolysis 2014; 37:217-233.
14) Wang L, Zhang D, Raghavan N, et al. In vitro assessment of met abolic drug-drug interaction potential of apixaban through cy tochrome P450 phenotyping, inhibition, and induction studies. Drug Metab Dispos 2010; 38:448-458.
15) A. Greinacher, T. Thiele, K. Selleng, Reversal of anticoagulants: an overview of current developments, Thromb. Haemost. 2015; 113:931-942.
16) C.V. Pollack Jr., P.A. Reilly, J. Eikelboom, et al., Idarucizumab for Dabigatran Reversal, N. Engl. J. Med. 2015; 373; 511-520.
17) G. Lu, F.R. DeGuzman, S.J. Hollenbach, et al., A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa, Nat.Med.2013; 19: 446-451.
18) K. Ghadimi, K.E. Dombrowski, J.H. Levy, I.J. Welsby, Andexanet alfa for the reversal of factor Xa inhibitor related anticoagulation, Expert. Rev. Hematol. 2016; 9:115-122.
19) M.L.G. Crowther, G. Lu, J. Leeds, J. Lin, P. Pratikhya, P.B. Conley, S. Connolly, J.T. Curnutte, A phase 2 randomized, double-blind, placebo-controlled trial demonstrat ing reversal of edoxabaninduced anticoagulation in healthy subjects by andexanet alfa (PRT064445): a universal antidote for factor Xa (fXa) inhibitors, Blood 2014; 124: 4269.
20) SDCEP: Managementof dental patients taking anticoagulants or antiplatelet drugs: dental clinical guidance. (http://www.sdcep.org. uk/wp-content/uploads/2015/09/SDCEP-Anticoagulants-Guidance.pdf)